EP4709753A1 - Inhibiteurs de slc4a4/nbce1 - Google Patents

Inhibiteurs de slc4a4/nbce1

Info

Publication number
EP4709753A1
EP4709753A1 EP24724494.0A EP24724494A EP4709753A1 EP 4709753 A1 EP4709753 A1 EP 4709753A1 EP 24724494 A EP24724494 A EP 24724494A EP 4709753 A1 EP4709753 A1 EP 4709753A1
Authority
EP
European Patent Office
Prior art keywords
nbcel
slc4a4
inhibiting
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24724494.0A
Other languages
German (de)
English (en)
Inventor
Massimiliano Mazzone
Marie-Pauline ORBAN
Janine BRUNNER
Stephan Schenk
Bruno Dombrecht
Tobias LANGENBERG
Michele CURCIO
Gholamreza Hassanzadeh Ghassabeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Original Assignee
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB, Vrije Universiteit Brussel VUB filed Critical Katholieke Universiteit Leuven
Publication of EP4709753A1 publication Critical patent/EP4709753A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgation concerne des composés inhibant sélectivement l'élément 4 de la famille 4 des porteurs de soluté/le cotransporteur 1 de bicarbonate de sodium électrogène (SLC4A4/NBCe1). Plus particulièrement, lesdits composés sont des anticorps à domaine unique inhibant SLC4A4/NBCe1, des composés comprenant au moins un polypeptide CDR d'un anticorps à domaine unique inhibant SLC4A4/NBCe1, et des composés comprenant un anticorps à domaine unique inhibant SLC4A4/NBCe1. Des utilisations des composés inhibant SLC4A4/NBCe1 sont également divulguées.
EP24724494.0A 2023-05-11 2024-05-06 Inhibiteurs de slc4a4/nbce1 Pending EP4709753A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23172907 2023-05-11
PCT/EP2024/062462 WO2024231348A1 (fr) 2023-05-11 2024-05-06 Inhibiteurs de slc4a4/nbce1

Publications (1)

Publication Number Publication Date
EP4709753A1 true EP4709753A1 (fr) 2026-03-18

Family

ID=86331833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24724494.0A Pending EP4709753A1 (fr) 2023-05-11 2024-05-06 Inhibiteurs de slc4a4/nbce1

Country Status (4)

Country Link
EP (1) EP4709753A1 (fr)
CN (1) CN121511260A (fr)
IL (1) IL324501A (fr)
WO (1) WO2024231348A1 (fr)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
CA2241433A1 (fr) 1997-08-19 1999-02-19 Smithkline Beecham Laboratoires Pharmaceutiques Nouveaux composes
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
CA2355968A1 (fr) * 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Proteine et adn associe
EP1141711A1 (fr) 1999-01-05 2001-10-10 Unilever Plc Fixation de fragments d'anticorps a des supports solides
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
CA2370351A1 (fr) 1999-04-22 2000-11-02 Unilever Plc Inhibition d'une infection virale au moyen de proteines de liaison a l'antigene monovalentes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2001040310A2 (fr) 1999-11-29 2001-06-07 Unilever Plc Immobilisation de proteines
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (fr) 2001-12-11 2004-09-15 AlgoNomics N.V. Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes
EP1456237A2 (fr) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Procede de clonage de sequences de domaines variables
CA2471645A1 (fr) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Nouveaux immunoconjugues utiles pour le traitement de tumeurs
EP1558645B1 (fr) 2002-11-08 2011-07-27 Ablynx N.V. Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation
WO2004041863A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
EP1656128A4 (fr) 2003-08-12 2007-02-28 William M Yarbrough Traitement de l'acne simple et procede d'utilisation
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
MX2007011735A (es) 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
EP2121757A2 (fr) 2007-02-21 2009-11-25 Ablynx N.V. Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
CA2687903C (fr) 2007-05-24 2016-09-13 Ablynx N.V. Sequences d'acides amines dirigees contre rank-l et polypeptides comprenant ces dernieres, destines au traitement de maladies et affections osseuses
EP2723771B1 (fr) 2011-06-23 2019-09-11 Ablynx NV Protéines se liant à la sérumalbumine
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
CA3070253A1 (fr) 2017-07-19 2019-01-24 Vib Vzw Agents de liaison a la l'albumine serique
WO2022175392A1 (fr) 2021-02-17 2022-08-25 Vib Vzw Inhibition de slc4a4 dans le traitement du cancer
EP4294516A1 (fr) 2021-02-19 2023-12-27 Vib Vzw Liants de récepteur de mannose-6-phosphate indépendants des cations

Also Published As

Publication number Publication date
IL324501A (en) 2026-01-01
CN121511260A (zh) 2026-02-10
WO2024231348A1 (fr) 2024-11-14

Similar Documents

Publication Publication Date Title
EP3818086B1 (fr) Traitement et prévention du cancer à l'aide de molécules de liaison à l'antigène her3
JP7314356B2 (ja) 改変ｊ鎖を有する結合分子
US11780933B2 (en) HER3 antigen-binding molecules
CN112703205B (zh) 抗间皮素抗体
JP6907124B2 (ja) Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
KR20230146578A (ko) Bcma, gprc5d, 및 cd3을 표적화하는 삼중특이적 항체
KR102875986B1 (ko) Il27 수용체 결합과 관련된 조성물 및 방법
CN110835375B (zh) 一种抗pd-1/egfr双特异性抗体及其用途
KR20200003845A (ko) 이중특이성 재조합단백질 및 이의 응용
CN112442122B (zh) 阻断型pd-1纳米抗体及其编码序列和用途
JP7430924B2 (ja) 拮抗的抗原結合タンパク質
US20240209106A1 (en) Anti-cd137 antibodies and methods of use
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
CN121358777A (zh) 抗mageb2的抗原结合蛋白
EP4709753A1 (fr) Inhibiteurs de slc4a4/nbce1
EP4613774A1 (fr) Anticorps à domaine unique ciblant ror1 humain
WO2025218621A1 (fr) Protéine de liaison à l'antigène ciblant muc1
WO2024173565A2 (fr) Anticorps synthétiques humains ciblant des mutations du récepteur 2 du facteur de croissance épidermique humain (her2)
HK40052624A (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules
KR20220155588A (ko) Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법
HK40026637A (en) Her3 antigen-binding molecules
HK40026637B (en) Her3 antigen-binding molecules

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR